Can I legally import corticotropin into the EU for personal use?

No. Importing unauthorised medicines into the EU is illegal under EU pharmaceutical law, even for personal use. This includes purchasing from non-EU sources or grey-market suppliers. Customs may confiscate shipments, and individuals can face legal penalties. The only legal pathway is via authorised clinical trials or compassionate use approved by your national health authority.

Is corticotropin available in any EU member state under a different approval route?

Individual member states can grant national approvals for unauthorised medicines in rare circumstances, but this is uncommon for corticotropin. Most EU countries align with EMA decisions. Your national medicines authority can advise on local procedures. Germany's BfArM and France's ANSM handle national approvals, but these are typically reserved for orphan indications.

Has the EMA ever reviewed corticotropin for approval?

There is no public record of a formal EMA centralised procedure application for corticotropin in recent decades. It's possible corticotropin products were approved under older national procedures before the centralised system existed. You can search the EMA's public registry to confirm current authorisation status.

What's the difference between EMA approval and clinical trial access?

EMA approval allows lawful prescription and dispensing by any licensed pharmacy. Clinical trial access is restricted to enrolled participants following a specific research protocol. Trial participation is temporary and subject to trial endpoints. They are not interchangeable from a legal or accessibility standpoint.

Are there approved alternatives to corticotropin in the EU?

Yes. Depending on the indication, other peptides and corticosteroids are EMA-approved. Discuss specific alternatives with your doctor. For example, some peptide therapies like [Abaloparatide](/compounds/abaloparatide) are approved for osteoporosis in the EU, though they are distinct from corticotropin mechanistically.

Is Corticotropin Legal in the EU? Current Status & Regulations

Corticotropin is not authorised for use in the European Union. While the compound is FDA-approved in the United States and has a robust evidence base spanning 185 clinical trials, the European Medicines Agency (EMA) has not granted market authorisation. This means corticotropin cannot be legally prescribed, dispensed, or marketed by licensed pharmacies across EU member states. However, the regulatory landscape varies by indication and individual country frameworks. Understanding the distinction between EMA authorisation, clinical trial access, and compassionate use pathways is essential for anyone researching this hormone.

The Core Legal Status: Why Corticotropin Isn't Authorised in the EU

Corticotropin—also called adrenocorticotropic hormone (ACTH)—is a naturally occurring peptide that stimulates cortisol production. In the United States, corticotropin products are FDA-approved for specific indications including multiple sclerosis exacerbations and infantile spasms. The compound benefits from a strong clinical trial portfolio: over 185 registered trials document its effects.

The EMA, however, has not authorised corticotropin as a centrally approved medicine. This is the key regulatory fact. Without EMA approval, the compound cannot be legally marketed, prescribed, or dispensed through standard pharmaceutical channels in any EU member state. Each member state (Germany, France, Spain, etc.) is bound by EMA decisions on centralised procedures, meaning a rejection at the EU level effectively closes legal access across the bloc.

Why Hasn't the EMA Approved Corticotropin?

The reasons are not always transparent, but several factors typically influence EMA decisions:

Evidence Standards. The EMA often requires different risk-benefit profiles than the FDA. A meta-analysis examining corticotropin's efficacy in adrenocortical insufficiency showed strong evidence, but the EMA may have requested additional safety data in specific populations or longer follow-up periods that manufacturers did not provide.

Manufacturing & Quality. EMA approval requires compliance with European Good Manufacturing Practice (GMP) standards, which differ from FDA requirements. Some corticotropin products (particularly synthetic ACTH formulations) may not have undergone the full European authorisation pathway.

Market Economics. Rare disease indications or niche conditions may not justify the cost of the EMA centralised procedure (€200,000+) if the addressable EU market is small.

Historical Timing. Corticotropin is an older compound. Products approved decades ago under different regulatory frameworks may not have been retroactively updated for modern EMA requirements.

Clinical Trial Access & Compassionate Use Pathways

Lack of EMA approval does not mean zero access. Researchers and patients in the EU may access corticotropin through:

Expanded Access (Compassionate Use). EU regulation allows member states to permit use of unauthorised medicines in life-threatening situations when no alternative exists. This requires physician request and national health authority approval on a case-by-case basis. Procedures vary by country.

Clinical Trials. PubMed lists ongoing and recent trials of corticotropin across Europe, primarily in academic research settings. Enrolment is limited and specific to trial protocols.

Named Patient Programmes. Some manufacturers offer named patient (special access) schemes, though availability is irregular and depends on the patient's jurisdiction.

These pathways are narrow and not equivalent to legal prescription availability.

How This Differs from US & Canada Status

For context: in the United States, corticotropin is FDA-approved under the brand name H.P. Acthar Gel and other formulations. In Canada, Health Canada has not approved corticotropin for most indications, placing Canada closer to the EU position.

This creates a regulatory fragmentation where the same molecule is legal in one jurisdiction, unavailable in another, and restricted in a third. For patients and clinicians, this underscores the importance of understanding your local regulatory environment.

Related Peptides & Alternatives in the EU

Patients or researchers investigating corticotropin in the EU context should be aware of alternative compounds and their approval statuses. Abaloparatide, for example, is EMA-approved for osteoporosis in both women and men, including male osteoporosis indications. While mechanistically distinct from corticotropin, it illustrates how similar peptides can achieve EU approval through the centralised procedure.

Other investigational compounds under study in Europe include ARA-290 and ACE-031, which may offer alternative mechanisms in select indications. Afamelanotide is another EMA-approved peptide (for erythropoietic protoporphyria) that shows how peptide medicines can navigate the EU approval process successfully.

Key Takeaways for EU Residents & Researchers

Corticotropin is not legally available through standard EU pharmacies or prescriptions.
The EMA has not granted authorisation, and there is no publicly announced timeline for application or approval.
Off-label or grey-market sources do not constitute legal access and carry significant regulatory and safety risks.
Clinical trial participation and compassionate use are the only legal pathways, and both are restrictive.
Regulatory status differs across jurisdictions—the US and Canada have different approval landscapes.

If you are a healthcare provider or patient in the EU seeking corticotropin for a specific indication, the appropriate first step is consultation with your national health authority or EMA regarding expanded access procedures. Self-sourcing or importing unauthorised medicines is illegal and exposes individuals to counterfeit, contaminated, or sub-potent products.

The Broader Context: EMA Approval Is Rigorous

The EMA's absence of approval for corticotropin should not be read as a rejection of the compound's efficacy. Rather, it reflects the regulatory reality that not all medicines approved in one jurisdiction will pursue or achieve approval in another. The EMA's approval standards are among the most stringent globally, and market authorisation requires a manufacturer's commitment to the centralised procedure, dossier preparation, and ongoing compliance with European standards.